A citation-based method for searching scientific literature

Jeffrey S Freeman. J Am Osteopath Assoc 2012
Times Cited: 4







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
Helena W Rodbard, Paul S Jellinger, Jaime A Davidson, Daniel Einhorn, Alan J Garber, George Grunberger, Yehuda Handelsman, Edward S Horton, Harold Lebovitz, Philip Levy,[...]. Endocr Pract 2009
678
50

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
50

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan.
Yehuda Handelsman, Jeffrey I Mechanick, Lawrence Blonde, George Grunberger, Zachary T Bloomgarden, George A Bray, Samuel Dagogo-Jack, Jaime A Davidson, Daniel Einhorn, Om Ganda,[...]. Endocr Pract 2011
324
50

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
50

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
897
25

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
939
25

Hypoglycemia, diabetes, and cardiovascular events.
Cyrus V Desouza, Geremia B Bolli, Vivian Fonseca. Diabetes Care 2010
248
25

A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education.
Diane Wild, Robyn von Maltzahn, Elaine Brohan, Torsten Christensen, Per Clauson, Linda Gonder-Frederick. Patient Educ Couns 2007
317
25

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
Bernard Zinman, John Gerich, John B Buse, Andrew Lewin, Sherwyn Schwartz, Philip Raskin, Paula M Hale, Milan Zdravkovic, Lawrence Blonde. Diabetes Care 2009
618
25

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Bernard Zinman, Byron J Hoogwerf, Santiago Durán García, Denái R Milton, Joseph M Giaconia, Dennis D Kim, Michael E Trautmann, Robert G Brodows. Ann Intern Med 2007
345
25

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Michael Nauck, Anders Frid, Kjeld Hermansen, Nalini S Shah, Tsvetalina Tankova, Ismail H Mitha, Milan Zdravkovic, Maria Düring, David R Matthews. Diabetes Care 2009
783
25


Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
389
25

Incretin-based therapies for type 2 diabetes mellitus.
Julie A Lovshin, Daniel J Drucker. Nat Rev Endocrinol 2009
472
25


Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
David C Klonoff, John B Buse, Loretta L Nielsen, Xuesong Guan, Christopher L Bowlus, John H Holcombe, Matthew E Wintle, David G Maggs. Curr Med Res Opin 2008
547
25


Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents.
John B Buse, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Cheng-Tao Chang, Yizhen Xu, Lawrence Blonde, Julio Rosenstock. Diabetes Care 2010
139
25

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
765
25

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits.
Daniel J Drucker, Steven I Sherman, Fred S Gorelick, Richard M Bergenstal, Robert S Sherwin, John B Buse. Diabetes Care 2010
196
25

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
536
25

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
25

Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring.
Cyrus Desouza, Holger Salazar, Benjamin Cheong, Joseph Murgo, Vivian Fonseca. Diabetes Care 2003
248
25

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
717
25


Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
Mark S Fineman, Thomas A Bicsak, Larry Z Shen, Kristin Taylor, Eling Gaines, Amanda Varns, Dennis Kim, Alain D Baron. Diabetes Care 2003
264
25


Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
864
25


Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Robert J Heine, Luc F Van Gaal, Don Johns, Michael J Mihm, Mario H Widel, Robert G Brodows. Ann Intern Med 2005
600
25


Polypharmacy and medication adherence in patients with type 2 diabetes.
Richard W Grant, Nicole G Devita, Daniel E Singer, James B Meigs. Diabetes Care 2003
221
25

The barrier of hypoglycemia in diabetes.
Philip E Cryer. Diabetes 2008
408
25



Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
25


Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
Orville G Kolterman, John B Buse, Mark S Fineman, Eling Gaines, Sonja Heintz, Thomas A Bicsak, Kristin Taylor, Dennis Kim, Maria Aisporna, Yan Wang,[...]. J Clin Endocrinol Metab 2003
421
25

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.
James D Lewis, Assiamira Ferrara, Tiffany Peng, Monique Hedderson, Warren B Bilker, Charles P Quesenberry, David J Vaughn, Lisa Nessel, Joseph Selby, Brian L Strom. Diabetes Care 2011
430
25

The impact of treatment noncompliance on mortality in people with type 2 diabetes.
Craig J Currie, Mark Peyrot, Christopher Ll Morgan, Chris D Poole, Sara Jenkins-Jones, Richard R Rubin, Christopher M Burton, Marc Evans. Diabetes Care 2012
121
25

Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort.
James D Best, Paul L Drury, Timothy M E Davis, Marja-Riitta Taskinen, Y Antero Kesäniemi, Russell Scott, Christopher Pardy, Merryn Voysey, Anthony C Keech. Diabetes Care 2012
25
25



Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study.
Mark Peyrot, Richard R Rubin, Torsten Lauritzen, Soren E Skovlund, Frank J Snoek, David R Matthews, Rüdiger Landgraf, Line Kleinebreil. Diabetes Care 2005
541
25

Correlates of insulin injection omission.
Mark Peyrot, Richard R Rubin, Davida F Kruger, Luther B Travis. Diabetes Care 2010
253
25

Barriers to insulin initiation: the translating research into action for diabetes insulin starts project.
Andrew J Karter, Usha Subramanian, Chandan Saha, Jesse C Crosson, Melissa M Parker, Bix E Swain, Howard H Moffet, David G Marrero. Diabetes Care 2010
162
25

Barriers to insulin injection therapy: patient and health care provider perspectives.
Richard R Rubin, Mark Peyrot, Davida F Kruger, Luther B Travis. Diabetes Educ 2009
86
25

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
25

Decreases in diabetes-free life expectancy in the U.S. and the role of obesity.
Solveig A Cunningham, Fernando Riosmena, Jing Wang, James P Boyle, Deborah B Rolka, Linda S Geiss. Diabetes Care 2011
11
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.